Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Verheugt, F. W.A.
Right arrow Articles by Antman, E. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Verheugt, F. W.A.
Right arrow Articles by Antman, E. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

The European Society of Cardiology

Introduction

Freek W.A. Verheugta,* and Elliott M. Antmanb

a Department of Cardiology, Heart Centre, University Medical Centre, P.O. Box 9101, St. Radboud, Nijmegen, The Netherlands
b Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

* Tel.: +31-24-361-4220; fax: +31-24-354-0537
f.verheugt@cardio.umcn.nl

eantman@rics.bwh.harvard.edu

The first 10% of the full text of this article appears below.

Arterial thrombosis is the underlying pathophysiological cause behind coronary arterial disease and ischaemic stroke, and arises as a result of a complex interplay between the ruptured arterial plaque, activation of platelets, and the coagulation cascade. Given the central role that coagulation factor thrombin (Factor ll) plays in thombus formation via fibrin formation and platelet activation, anticoagulant . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?